Interleukin 17 and Its Involvement in Renal Cell Carcinoma

J Clin Med. 2022 Aug 24;11(17):4973. doi: 10.3390/jcm11174973.

Abstract

Nowadays, molecular and immunological research is essential for the better understanding of tumor cells pathophysiology. The increasing number of neoplasms has been taken under 'the molecular magnifying glass' and, therefore, it is possible to discover complex relationships between the cytophysiology and immune system action. An example could be renal cell carcinoma (RCC) which has deep interactions with immune mediators such as Interleukin 17 (IL-17)-an inflammatory cytokine reacting to tissue damage and external pathogens. RCC is one of the most fatal urological cancers because of its often late diagnosis and poor susceptibility to therapies. IL-17 and its relationship with tumors is extremely complex and constitutes a recent topic for numerous studies. What is worth highlighting is IL-17's dual character in cancer development-it could be pro- as well as anti-tumorigenic. The aim of this review is to summarize the newest data considering multiple connections between IL-17 and RCC.

Keywords: Th17 lymphocytes; immunotherapy; inflammation; interleukin-17; renal cell carcinoma; tumor development; tumor microenvironment.

Publication types

  • Review